Business Wire

KYOTO-SEMICONDUCTOR

13.9.2021 09:02:07 CEST | Business Wire | Press release

Share
Kyoto Semiconductor Announces New High-power Photovoltaic Power Converter

Kyoto Semiconductor Co., Ltd. (President and CEO Tsuneo Takahashi, Head office: Fushimi-ku, Kyoto city), a leading optical device solution manufacturer with world-class technologies and Japanese quality, has announced the new high-power photovoltaic power converter, KPC8H-FC.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005220/en/

It has been 10 years since the company announced its existing model; KPC8-T optical power converter in 2011. Up to now, it has been adopted in various applications using optical power transmission*1 over optical fiber, such as the aircraft equipment, the equipment sensitive to electromagnetic noise, or the equipment in a remote place where the power transmission is difficult. The new high-power photovoltaic power converter KPC8H-FC has improved two features that many KPC8-T customers requested.

High Power: By improving the efficiency, the electrical output has been increased 1.3 times compared to our existing product*2 under the same optical input power. In addition, due to the improvement of heat dissipation, the rated value of the maximum optical power input has been tripled compared to that of conventional product*2 . The new applications which require higher output can be enabled with KPC8H-FC.

Small Form Factor: While the existing product*2 is a pigtail module with single mode optical fiber, KPC8H-FC adopts the small form factor which is integrated in the FC receptacle. It can be directly attached to the operation panel of the equipment (panel mount). Since it saves space, it can contribute to the reduction of the equipment size.

Sample shipment of the KPC8H-FC high-power photovoltaic power converter is scheduled to begin on September 15, 2021, and mass production is expected to start on April 28, 2022.

For more information on KPC8H-FC, visit: https://www.kyosemi.co.jp/en/products/kpc8h-fc/

*1 Optical power transmission: A method of transmitting power using a photoelectric conversion element for laser light over an optical fiber cable or wireless. Since laser power transmission over optical fiber cables has less loss than metal wires and can be completely electrically isolated, it is possible to transmit power to outdoor equipment or remote equipment where the surge protection is required and the metal wires are difficult to use, or where the electromagnetic noise is strong.

*2 Kyoto Semiconductor’s current photovoltaic power converter KPC8-T: https://www.kyosemi.co.jp/en/products/kpc8-t/

About Kyoto Semiconductor
Kyoto Semiconductor was established in 1980 in Kyoto as a dedicated manufacturer of optical semiconductors. The semiconductors manufactured offer superlative performance and precision, suited for use in optical transmission. They are manufactured end-to-end, including pre- and post-processing, and together with Kyoto Semiconductor’s unique packaging technology, at our location in Japan and made available to customers around the world. Kyoto Semiconductor leads the industry with world-standard technologies for optical device solutions based on Japanese quality and attention to production detail.

Company Website: https://www.kyosemi.co.jp/

* Product names, company names, and organization names mentioned in this press release are trademarks or registered trademarks of their respective companies.
* All contents of this press release are as of the date of publication. Subject to change without notice. Please understand in advance.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release

New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release

Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye